Previous 10 | Next 10 |
National Eye Institute (NEI) to Collaborate with Curative Biotechnology under Cooperative Research and Development Agreement (CRADA) Boca Raton, FL, May 03, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or t...
Curative (OTCPK:CUBT) announced a cooperative research and development agreement with the National Eye Institute (NEI), to test the company's ocular metformin formulation to treat intermediate and late-stage age-related macular degeneration (AMD) disease. Age-related macular de...
Curative Biotechnology Announces Cooperative Research and Development Agreement(CRADA) with the National Eye Institute (NEI) for Clinical Evaluation of its Proprietary Ocular Metformin Formulation in Age-Related Macular Degeneration Emily Y. Chew, M.D. of the National Eye Instit...
Emily Y. Chew, M.D. of the National Eye Institute Assigned Principal Investigator Boca Raton, FL, March 21, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focus...
Company’s First I n -license Pipeline P roduct to E nter P re- clinical S tudies Boca Raton, FL, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company...
Company’s First I n -license Pipeline P roduct to E nter P re- clinical S tudies Boca Raton, FL, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company...
Dr. Sohn to Oversee Development of Next Gen COVID-19 Vaccine to Treat Kidney Failure Patients , Late-Stage Rabies Therapeutic and Age-related Macular Degeneration Boca Raton, FL, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (...
Curative Biotechnology (OTCPK:CUBT +3.7%) reaches an agreement with Mid-Atlantic BioTherapeutics to broaden its previously announced license of IMT504. The license is a novel patented immunotherapy and adjuvant, to include the development of a next generation COVID-19 vaccine. The c...
License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License Beyond Treatment of Symptomatic Rabies Boca Raton, FL, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company...
Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License Beyond Treatment of Symptomatic Rabies PR Newswire BOCA RATON, Fla. , ...
News, Short Squeeze, Breakout and More Instantly...
Curative Biotechnology Inc Com Company Name:
CUBT Stock Symbol:
OTCMKTS Market:
Curative Biotechnology Inc Com (CUBT) is expected to report for Q1 2022
Appointment of Independent Director Nominee to become effective upon approval by and listing of common stock on a National Exchange Boca Raton, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), ...
Appointment of Independent Director to become effective upon approval by and listing of common stock on a National Exchange Boca Raton, FL, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a develo...